サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：妊産婦メンタルヘルス市場- - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）- （適応疾患別、治療法別、地域別、企業別）
市場調査レポート
商品コード
1358262

妊産婦メンタルヘルス市場- - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）- （適応疾患別、治療法別、地域別、企業別）

Maternal Mental Health Market - Global Maternal Mental Health Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Disease Indication Coverage, By Therapy Coverage, By Geographic Coverage and By Company)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 270 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
妊産婦メンタルヘルス市場- - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）- （適応疾患別、治療法別、地域別、企業別）
出版日: 2023年09月06日
発行: Fairfield Market Research
ページ情報: 英文 270 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の妊産婦メンタルヘルスの市場規模は、2023年～2030年にかけてのCAGR28％という堅調な伸びを背景に、2030年末までに400億米ドルという大幅な評価を達成する勢いです。この前例のない成長は、妊産婦死亡率の減少を目的とした政府資金の増加、産後うつ病の発生率の急増、啓発プログラムの拡大、妊産婦メンタルヘルスに関連する実践を強化するための継続的な取り組みなど、いくつかの重要な要因によるものです。

妊産婦メンタルヘルス市場の急速な拡大は、前向きな償還シナリオ、産後うつ病（PPD）の有病率の上昇、広範な意識向上イニシアチブの実施、強固で信頼できるヘルスケアインフラの存在など、極めて重要な要因の組み合わせによって支えられています。

産後うつ病は、産後の母親の精神的幸福に重大な影響を及ぼす疾患であり、その広範な発生と深刻な影響により、妊産婦メンタルヘルス分野で最大の市場シェアを占めています。

対人関係療法（IPT）は、人間関係に基づくストレス要因に対処し、周産期の母親の幸福を高める効果があることで知られ、妊産婦メンタルヘルス市場における主要な治療アプローチとして台頭してきました。

北米は妊産婦メンタルヘルス市場の最前線にあり続け、専門的ケア、カウンセリングサービス、支援グループへのアクセス強化の恩恵を受けています。同地域の先進的なヘルスケアインフラと妊産婦メンタルヘルスに対する積極的なアプローチが、同地域の主導的地位に貢献しています。

アジア太平洋は、妊産婦メンタルヘルス問題に対する意識が急上昇しており、最も急成長している市場として浮上しています。同地域の経済成長により、ヘルスケアインフラが整備され、医療施設へのアクセスが向上し、女性の健康が重視されるようになっています。

当レポートでは、世界の妊産婦メンタルヘルス市場について調査し、市場の概要とともに、適応疾患別、治療法別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の妊産婦メンタルヘルス市場の見通し、2018年～2030年

  • 世界の妊産婦メンタルヘルス市場の見通し、適応疾患別、金額（10億米ドル）、2018年～2030年
  • 世界の妊産婦メンタルヘルス市場の見通し、治療法別、金額（10億米ドル）、2018年～2030年
  • 世界の妊産婦メンタルヘルス市場の見通し、地域別、金額（10億米ドル）、2018年～2030年

第4章 北米の妊産婦メンタルヘルス市場の見通し、2018年～2030年

第5章 欧州の妊産婦メンタルヘルス市場の見通し、2018年～2030年

第6章 アジア太平洋の妊産婦メンタルヘルス市場の見通し、2018年～2030年

第7章 ラテンアメリカの妊産婦メンタルヘルス市場の見通し、2018年～2030年

第8章 中東・アフリカの妊産婦メンタルヘルス市場の見通し、2018年～2030年

第9章 競合情勢

  • 疾患の適応と用途のヒートマップ
  • メーカーと用途のヒートマップ
  • 企業の市場シェア分析、2022年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Pfizer, Inc.
    • Lipocine, Inc.
    • Viatris Inc.
    • GlaxoSmithKline plc
    • Alembic Pharmaceuticals Limited
    • Mallinckrodt, Inc.
    • Sage Therapeutics, Inc.
    • Bold Health
    • Bausch Health Companies Inc.
    • Magellan Health, Inc.

第10章 付録

目次

Global Maternal Mental Health Market Poised for Remarkable Growth, Projected to Reach US$40 Billion by 2030.

The global maternal mental health market is on track to achieve a substantial valuation of US$40 billion by the close of 2030, driven by a robust compound annual growth rate (CAGR) of 28% during the period from 2023 to 2030. This unprecedented growth is attributed to several key factors, including increased government funding aimed at reducing maternal mortality, a surge in the incidence of postpartum depression, expanding awareness programs, and ongoing efforts to enhance practices related to maternal mental health.

Market Insights in Brief

The maternal mental health market's rapid expansion is underpinned by a combination of pivotal drivers, including positive reimbursement scenarios, a rising prevalence of postpartum depression (PPD), the implementation of widespread awareness initiatives, and the presence of a robust and reliable healthcare infrastructure.

Postpartum depression, a condition with significant implications for the mental well-being of postpartum mothers, commands the largest market share in the maternal mental health sector due to its widespread occurrence and profound impact.

Interpersonal therapy (IPT) has emerged as a leading therapeutic approach in the maternal mental health market, known for its effectiveness in addressing relationship-based stressors and enhancing maternal well-being during the perinatal period.

Regional Dynamics

North America remains at the forefront of the maternal mental health market, benefiting from enhanced accessibility to specialized care, counseling services, and support groups. The region's advanced healthcare infrastructure and proactive approach towards maternal mental health have contributed to its leadership position.

Asia Pacific, experiencing a surge in awareness about maternal mental health issues, is emerging as the fastest-growing market. The region's economic growth has led to improved healthcare infrastructure, increased access to medical facilities, and a growing emphasis on women's health.

Growth Drivers

  • 1. Growing Government Funds Targeting Reduced Maternal Mortality

Government investments in mental health services and support for pregnant and postpartum women have played a pivotal role in reducing the risk of maternal mental health disorders. These funds have led to the expansion of maternal mental health services, including early detection, counseling, specialized clinics, and awareness campaigns, thereby reducing stigma and encouraging more women to seek help during pregnancy and postpartum periods.

  • 2. Growing Incidences of Postpartum Depression

The rising prevalence of postpartum depression, coupled with improved screening and detection measures, has resulted in a higher demand for maternal mental health services. Timely intervention for postpartum depression is recognized as crucial to prevent long-term impacts on both mother and child well-being, further driving market growth.

Challenges

Mental Health Workforce Shortage

Despite the growing demand for mental health services during the perinatal period, a shortage of qualified experts remains a significant constraint. This scarcity leads to long wait times for appointments, limited access to specialized treatment, and delayed interventions, potentially affecting the health outcomes of pregnant and postpartum women.

Competitive Landscape

Key players in the maternal mental health market include: Lipocine, Inc., Pfizer, Inc., Viatris, Inc., Bold Health, GlaxoSmithKline Inc., Alembic Pharmaceuticals Limited, Mallinckrodt, Inc., Sage Therapeutics, Inc., Bausch Health Companies Inc., and Magellan Health, Inc.

The global maternal mental health market's remarkable growth trajectory underscores its pivotal role in safeguarding the well-being of mothers and the health and development of their children. As governments, healthcare providers, and the private sector continue to invest in this critical healthcare segment, the market is poised to make substantial strides in the years ahead.

Table of Contents

1. Executive Summary

  • 1.1. Global Maternal Mental Health Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Maternal Mental Health Market Outlook, 2018 - 2030

  • 3.1. Global Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Postpartum Depression
      • 3.1.1.2. Dysthymia
      • 3.1.1.3. Pregnancy and Postpartum General Anxiety
      • 3.1.1.4. Pregnancy and Postpartum OCD
      • 3.1.1.5. Birth-Related PTSD
      • 3.1.1.6. Others
  • 3.2. Global Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Antidepressants
        • 3.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 3.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 3.2.1.1.3. Other
      • 3.2.1.2. Interpersonal Psychotherapy (IPT)
      • 3.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 3.2.1.4. Other
  • 3.3. Global Maternal Mental Health Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Maternal Mental Health Market Outlook, 2018 - 2030

  • 4.1. North America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Postpartum Depression
      • 4.1.1.2. Dysthymia
      • 4.1.1.3. Pregnancy and Postpartum General Anxiety
      • 4.1.1.4. Pregnancy and Postpartum OCD
      • 4.1.1.5. Birth-Related PTSD
      • 4.1.1.6. Others
  • 4.2. North America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Antidepressants
        • 4.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 4.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 4.2.1.1.3. Other
      • 4.2.1.2. Interpersonal Psychotherapy (IPT)
      • 4.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 4.2.1.4. Other
    • 4.2.2. Market Attractiveness Analysis
  • 4.3. North America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 4.3.1.2. U.S. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 4.3.1.3. Canada Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 4.3.1.4. Canada Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Maternal Mental Health Market Outlook, 2018 - 2030

  • 5.1. Europe Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Postpartum Depression
      • 5.1.1.2. Dysthymia
      • 5.1.1.3. Pregnancy and Postpartum General Anxiety
      • 5.1.1.4. Pregnancy and Postpartum OCD
      • 5.1.1.5. Birth-Related PTSD
      • 5.1.1.6. Others
  • 5.2. Europe Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Antidepressants
        • 5.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 5.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 5.2.1.1.3. Other
      • 5.2.1.2. Interpersonal Psychotherapy (IPT)
      • 5.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 5.2.1.4. Other
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.2. Germany Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.3. U.K. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.4. U.K. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.5. France Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.6. France Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.7. Italy Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.8. Italy Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.9. Turkey Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.10. Turkey Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.11. Russia Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.12. Russia Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.13. Rest Of Europe Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.14. Rest Of Europe Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Maternal Mental Health Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Postpartum Depression
      • 6.1.1.2. Dysthymia
      • 6.1.1.3. Pregnancy and Postpartum General Anxiety
      • 6.1.1.4. Pregnancy and Postpartum OCD
      • 6.1.1.5. Birth-Related PTSD
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Antidepressants
        • 6.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 6.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 6.2.1.1.3. Other
      • 6.2.1.2. Interpersonal Psychotherapy (IPT)
      • 6.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 6.2.1.4. Other
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.2. China Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.3. Japan Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.4. Japan Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.5. South Korea Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.6. South Korea Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.7. India Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.8. India Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.9. Southeast Asia Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.10. Southeast Asia Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.11. Rest of Asia Pacific Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.12. Rest of Asia Pacific Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Maternal Mental Health Market Outlook, 2018 - 2030

  • 7.1. Latin America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Postpartum Depression
      • 7.1.1.2. Dysthymia
      • 7.1.1.3. Pregnancy and Postpartum General Anxiety
      • 7.1.1.4. Pregnancy and Postpartum OCD
      • 7.1.1.5. Birth-Related PTSD
      • 7.1.1.6. Others
  • 7.2. Latin America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Antidepressants
        • 7.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 7.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 7.2.1.1.3. Other
      • 7.2.1.2. Interpersonal Psychotherapy (IPT)
      • 7.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 7.2.1.4. Other
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.2. Brazil Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.3. Mexico Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.4. Mexico Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.5. Argentina Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.6. Argentina Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.7. Rest of Latin America Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.8. Rest of Latin America Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Maternal Mental Health Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Postpartum Depression
      • 8.1.1.2. Dysthymia
      • 8.1.1.3. Pregnancy and Postpartum General Anxiety
      • 8.1.1.4. Pregnancy and Postpartum OCD
      • 8.1.1.5. Birth-Related PTSD
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Antidepressants
        • 8.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 8.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 8.2.1.1.3. Other
      • 8.2.1.2. Interpersonal Psychotherapy (IPT)
      • 8.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 8.2.1.4. Other
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.2. GCC Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.3. South Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.4. South Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.5. Egypt Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.6. Egypt Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.7. Nigeria Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.8. Nigeria Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.9. Rest of Middle East & Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.10. Rest of Middle East & Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Disease Indication vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Lipocine, Inc.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Viatris Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline plc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Alembic Pharmaceuticals Limited
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Mallinckrodt, Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Sage Therapeutics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Bold Health
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Bausch Health Companies Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Magellan Health, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations